Pacira reported $176.65M in Sales Revenues for its fiscal quarter ending in September of 2026.



Sales Change Date
Astellas Pharma JPY 629.95B 10.96B Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
J&J USD 25.4B 89M Sep/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Perrigo USD 989M 31M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Xeris Pharmaceuticals USD 92.1M 8.97M Jun/2026
Zoetis USD 2.4B 100M Sep/2026